Royalty Pharma 2026: Revenue $690.1M, EPS $0.32— 10-Q Summary
Royalty Pharma reported 2026 revenue of $690.1M, up 13.3% YoY, but net income fell 49.1% to $144.68M and EPS declined 51.5% to $0.32. Total income for the first nine months rose 13.6% to $2.0B. The company made acquisitions and saw FDA approvals for Rasonque and Mimrylo, but faced setbacks with Pelacarsen and Tazverik.
How this was made
The 30-second read
Why it matters
Earnings miss may trigger sell‑offs in the royalty pharma niche, but pipeline progress could mitigate long‑term concerns.
Market read
The report provides fresh earnings data that can affect trading decisions on RPRX and related biotech royalty stocks.
What to watch
Potential upside from upcoming drug approvals (e.g., Rasonque, Mimrylo) not yet reflected in the price.
Background
Royalty Pharma plc filed its 10‑Q for the 2026 quarter, showing mixed financial results.
Ticker impact
Q4 2026 revenue $690.1M (+13.3% YoY) and diluted EPS $0.32 (-51.5% YoY) reported in the 10‑Q.
downward pressure as the market prices in the earnings miss and lower EPS.
Revenue grew modestly while profit fell sharply, suggesting weaker profitability than expected.
Market effects
Biotech royalty sector may see broader valuation pressure after a major player reports earnings weakness.
U.S. biotech stocks could dip in early trading.
Limited to investors tracking royalty‑based pharma companies.
Counterpoint
If the revenue beat is viewed as a sign of resilient royalty streams, the stock could rebound on a short‑term bounce.
Key entities
- companyRoyalty Pharma plc
U.S.-listed royalty pharma company.
